2 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow InFlectis BioScience: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol) IFB-088 50mg/day, Placebo, Riluzole 100mg/day - Amyotrophic Lateral Sclerosis, ALS | Phase 2 | Completed | InFlectis BioScience | 51 | 2022-12-02 | 2025-10-10 |
| A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088 IFB-088 (2.5-60.0mg) oral capsule, Placebo (2.5-60.mg) oral capsule, IFB-088 (15.0-50.0mg) oral capsule - Healthy Volunteers | Phase 1 | Completed | InFlectis BioScience | 72 | 2018-06-21 | 2022-01-26 |
Amyotrophic Lateral Sclerosis (1) · Motor Neuron Disease (1) · Neurodegenerative Diseases (1)
Riluzole (1) · calcium D-pantothenate, L-cysteine drug combination (1)
France (2) · Italy (1)
Christine Audebert, MD (1) · Giuseppe Lauria, Pr (1) · Shahram Attarian, Pr (1)
2018 (1)